Fragment-based drug discovery.
Erlanson
Daniel A
DA
Sunesis Pharmaceuticals Inc., 341 Oyster Point Boulevard, South San Francisco, CA 94080, USA. erlanson@sunesis.com
McDowell
Robert S
RS
O'Brien
Tom
T
D000818:Animals; D018360:Crystallography, X-Ray; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000138:chemical synthesis* / Q000737:chemistry* / Q000494:pharmacology; D006801:Humans; D009682:Magnetic Resonance Spectroscopy; D013058:Mass Spectrometry; D008970:Molecular Weight; D011485:Protein Binding; D013329:Structure-Activity Relationship; D013678:Technology, Pharmaceutical
D004791:Enzyme Inhibitors